Gyre Therapeutics (GYRE) Income from Non-Controlling Interests (2023 - 2026)

Gyre Therapeutics (GYRE) has 4 years of Income from Non-Controlling Interests data on file, last reported at -$1.2 million in Q1 2026.

• Income from Non-Controlling Interests for Q1 2026 came in at -$1.2 million, down 212.64% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.6 million (down 40.4% YoY), and the FY2025 annual result was $4.9 million, down 16.51% from the prior year.
• Income from Non-Controlling Interests declined to -$1.2 million in Q1 2026 per GYRE's latest filing, from $357000.0 in the prior quarter.
• Over five years, Income from Non-Controlling Interests peaked at $3.5 million in Q3 2023 and troughed at -$1.2 million in Q1 2026.
• A 4-year average of $1.3 million and a median of $1.1 million in 2025 frame the typical range for Income from Non-Controlling Interests.
• The sharpest annual moves came in 2024 and 2026: Income from Non-Controlling Interests soared 2203.45% in 2024, then plunged 212.64% in 2026.
• A 4-year view of Income from Non-Controlling Interests shows it stood at $29000.0 in 2023, then soared by 2203.45% to $668000.0 in 2024, then plunged by 46.56% to $357000.0 in 2025, then plunged by 426.89% to -$1.2 million in 2026.
• Business Quant data shows GYRE's Income from Non-Controlling Interests at -$1.2 million in Q1 2026, $357000.0 in Q4 2025, and $2.3 million in Q3 2025.